RNS60

physically-modified saline containing charge-stabilized nanobubbles generated by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow under elevated oxygen pressure; it has immunosuppressive and anti-inflammatory properties

Networked: 12 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ghosh, Supurna: 9 articles (01/2020 - 01/2012)
2.	Pahan, Kalipada: 8 articles (01/2020 - 01/2012)
3.	Watson, Richard: 5 articles (03/2018 - 01/2012)
4.	Rangasamy, Suresh B: 4 articles (01/2020 - 05/2017)
5.	Mondal, Susanta: 3 articles (01/2018 - 01/2012)
6.	Bendotti, Caterina: 2 articles (01/2019 - 03/2018)
7.	Bonetto, Valentina: 2 articles (01/2019 - 03/2018)
8.	Watson, Richard L: 2 articles (01/2018 - 05/2017)
9.	Khasnavis, Saurabh: 2 articles (01/2014 - 08/2012)
10.	Roy, Avik: 2 articles (01/2014 - 08/2012)

Related Diseases

1.	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/01/2023 - "Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial." 01/01/2019 - "A pilot trial of RNS60 in amyotrophic lateral sclerosis."
2.	Disease Progression 03/01/2018 - "RNS60 protected motor neurons in in vitro paradigms and slowed the disease progression of C57BL/6-SOD1G93A mice through a significant protection of spinal motor neurons and neuromuscular junctions. " 03/01/2018 - "Transgenic SOD1G93A mice were treated with RNS60 or NS (300 μl/mouse intraperitoneally every other day) starting at the disease onset and examined for disease progression as well as pathological and biochemical alterations. " 01/01/2019 - "A large, multicenter, phase II trial of RNS60 is currently enrolling participants to test the effects of RNS60 on ALS biomarkers and disease progression. " 05/01/2017 - "Recently we have demonstrated that RNS60, administered through intraperitoneal injection, ameliorated clinical symptoms and disease progression of experimental allergic encephalomyelitis (EAE), an animal model of MS. Since the intravenous route is not preferred for treating a chronic condition, we tested if nebulization of RNS60 could attenuate the disease process of adoptively-transferred EAE in mice. "
3.	Hypoxia (Hypoxemia) 10/14/2022 - "This study indicates that RNS60 enhances cardioprotection in experimental myocardial hypoxia and under conditions of cardioplegic arrest. " 10/14/2022 - "We investigated the effects of RNS60 during cardiac hypoxia in mice and as an additive to cardioplegic solution in rat hearts. " 10/14/2022 - "RNS60 attenuated changes in the ECG STU area during hypoxia, while the troponin T concentration and creatine kinase activity were significantly higher in the serum of the controls. "
4.	Neurodegenerative Diseases (Neurodegenerative Disease) 01/01/2023 - "RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. " 01/01/2018 - "These results describe a novel property of RNS60 of enhancing mitochondrial biogenesis via PI 3-kinase-CREB-mediated up-regulation of PGC1α, which may be of therapeutic benefit in different neurodegenerative disorders." 08/24/2012 - "These results describe a novel anti-inflammatory property of RNS60 via type IA PI 3-kinase-Akt-CREB-mediated up-regulation of IκBα, which may be of therapeutic benefit in neurodegenerative disorders."
5.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/2012 - "Finally, RNS60 treatment exhibited immunomodulation and ameliorated adoptive transfer of experimental allergic encephalomyelitis, an animal model of MS, via Tregs. " 01/01/2018 - "Correction to: Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy." 05/01/2017 - "Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy." 05/01/2017 - "Recently we have demonstrated that RNS60, administered through intraperitoneal injection, ameliorated clinical symptoms and disease progression of experimental allergic encephalomyelitis (EAE), an animal model of MS. Since the intravenous route is not preferred for treating a chronic condition, we tested if nebulization of RNS60 could attenuate the disease process of adoptively-transferred EAE in mice. "

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)
2.	Troponin T (Troponin T1)
3.	Neuroprotective Agents
4.	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
5.	N-Methylaspartate (NMDA)
6.	Proteins (Proteins, Gene)
7.	Creatine Kinase (Creatine Phosphokinase)
8.	Cardioplegic Solutions
9.	Calcium

Related Therapies and Procedures

1.	Therapeutics
2.	Immunomodulation
3.	Intraperitoneal Injections